V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

Avanos Medical Executive Compensation (FY25)

AVNS · Executive and director compensation, fiscal 2023 to 2025
Chief executive, fiscal 2025
◇
David Pacitti
Median of the other named officers
$2,039,138
7 officers, excluding the chief executive
Latest say-on-pay support
=
April 24, 2025
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Avanos Medical brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (DEF 14A): March 12, 2026
13 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Avanos Medical brief$1,500Get the executive brief
Velarion Member, one year
359 figures on this page: 349 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Joseph Woody → David Pacitti
Say-on-pay support: 94.8% → 88.4% (6.4 points lower)
CEO pay ratio: 706.1:1 → 1,480:1 (109.6% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Avanos Medical's chief executive and what were they paid?
David Pacitti was paid $9,469,803 in total compensation as Chief Executive Officer for fiscal 2025.
What was Avanos Medical's say-on-pay result?
Shareholders supported the say-on-pay proposal with 88.4% of votes cast for or against in favor at the meeting held April 24, 2025 for fiscal 2024.
Which companies are in Avanos Medical's peer group?
The disclosed peer group includes Accuray Incorporated, AngioDynamics, Inc., AtriCure, Inc., Bioventus Inc. and CONMED Corporation, among others.
What is Avanos Medical's chief executive pay ratio?
The company reported a chief executive pay ratio of 1,480:1 for fiscal 2025, against median employee compensation of $9,963.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joseph Woody
Chief Executive Officer
◇—◇—◇—◇◇
Michael Greiner
Senior Vice President, Chief Financial Officer and Chief Transformation Officer
◇—◇—◇—◇◇
Kerr Holbrook
Senior Vice President and Chief Commercial Officer
◇—◇—◇—◇◇
Mojirade James
Senior Vice President, General Counsel and Secretary
◇—◇—◇—◇◇
Sudhakar Varshney
Senior Vice President, Global Supply Chain and Procurement
◇◇◇—◇—◇◇
William Haydon
Senior Vice President and General Manager, Pain Franchise
Departed during or after this year
◇◇————◇◇
Scott Galovan
Chief Financial Officer
◇—◇—◇——◇
Jason Pickett
Interim Chief Financial Officer
Served on an interim basis
◇—◇—◇——◇
Warren Machan
Former Interim Chief Financial Officer
Served on an interim basis
◇——————◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joseph Woody
Former Chief Executive Officer
Departed during or after this year
◇—◇—◇—◇◇
Michael Greiner
Interim Chief Executive Officer
Served on an interim basis
◇—◇—◇—◇◇
Kerr Holbrook
Senior Vice President and Chief Commercial Officer
◇—◇—◇—◇◇
Mojirade James
Senior Vice President, General Counsel and Secretary
◇—◇—◇—◇◇
Scott Galovan
Chief Financial Officer
◇—◇—◇——◇
Sigfrido Delgado
Senior Vice President, Operations
◇—◇—◇—◇— not reconciled
Jason Pickett
Interim Chief Financial Officer
Served on an interim basis
◇—◇—◇——◇
Warren Machan
Interim Chief Financial Officer
Served on an interim basis
◇——————◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Pacitti
Chief Executive Officer
◇◇◇—◇—◇◇
Michael Greiner
Former Interim Chief Executive Officer
Departed during or after this year
Served on an interim basis
◇—◇◇◇—◇◇
Kerr Holbrook
Former Senior Vice President and Chief Commercial Officer
Departed during or after this year
◇—◇◇◇—◇◇
Mojirade James
Former Senior Vice President, General Counsel and Secretary
Departed during or after this year
◇—◇◇◇—◇◇
Scott Galovan
Senior Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Sigfrido Delgado
Senior Vice President, Operations
◇—◇◇◇—◇◇
Jason Pickett
Interim Chief Financial Officer
Served on an interim basis
◇—◇—◇—◇◇
Warren Machan
Former Interim Chief Financial Officer
Departed during or after this year
Served on an interim basis
◇——————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
David C. PacittiRSU◇——◇——◇
David C. PacittiPSU◇—◇—◇—◇
Jason M. PickettRSU◇——◇——◇
Jason M. PickettRSU◇——◇——◇
Jason M. PickettPSU◇—◇—◇—◇
Kerr W. HolbrookPSU◇—◇—◇—◇
Kerr W. HolbrookRSU◇——◇——◇
Kerr W. HolbrookOPTION◇——◇—◇◇
Michael C. GreinerOPTION◇——◇—◇◇
Michael C. GreinerPSU◇—◇—◇—◇
Michael C. GreinerRSU◇——◇——◇
Mojirade A. JamesOPTION◇——◇—◇◇
Mojirade A. JamesRSU◇——◇——◇
Mojirade A. JamesPSU◇—◇—◇—◇
Mojirade A. JamesRSU◇——◇——◇
Scott M. GalovanPSU◇—◇—◇—◇
Scott M. GalovanRSU◇——◇——◇
Scott M. GalovanOPTION◇——◇—◇◇
Scott M. GalovanRSU◇——◇——◇
Scott M. GalovanRSU◇——◇——◇
Sigfrido DelgadoRSU◇——◇——◇
Sigfrido DelgadoPSU◇—◇—◇—◇
Sigfrido DelgadoRSU◇——◇——◇
Sigfrido DelgadoOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Sigfrido DelgadoPSU◇◇——
Option◇—◇3/7/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
Scott GalovanRSU◇◇——
Option◇—◇3/7/2035
Option◇—◇5/3/2028
Option◇—◇5/5/2026
PSU◇◇——
Option◇—◇5/7/2030
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇5/8/2029
Option◇—◇5/3/2027
RSU◇◇——
Kerr HolbrookOption◇—◇5/7/2030
Option◇—◇12/1/2030
PSU◇◇——
PSU◇◇——
PSU◇◇——
Jason PickettOption◇—◇5/8/2029
Option◇—◇5/3/2027
Option◇—◇5/5/2026
PSU◇◇——
PSU◇◇——
Option◇—◇5/3/2028
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇5/7/2030
RSU◇◇——
RSU◇◇——
Warren MachanOption◇—◇4/1/2026
Option◇—◇4/1/2026
Option◇—◇4/1/2026
Mojirade JamesOption◇—◇12/1/2030
PSU◇◇——
PSU◇◇——
PSU◇◇——
David PacittiPSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gary D. Blackford
Board chair
◇◇————◇
Patrick J. O'Leary
◇◇————◇
Dr. Julie Shimer
◇◇————◇
Indrani L. Franchini
◇◇————◇
Dr. Lisa Egbuonu-Davis
◇◇————◇
James L. Cunniff, David C. Pacitti and William P. Burke served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.
Stock ownership guideline: 5x annual Board base cash compensation

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Accuray Incorporated ARAY
  • AngioDynamics, Inc. ANGO
  • AtriCure, Inc. ATRC
  • Bioventus Inc. BVS
  • CONMED Corporation CNMD
  • ConvaTec Group Plc symbol not shown
  • Globus Medical Inc. GMED
  • ICU Medical, Inc. ICUI
  • Insulet Corporation PODD
  • Integer Holdings Corporation ITGR
  • Integra Lifesciences Holding IART
  • Lantheus Holdings, Inc. LNTH
  • Masimo Corporation MASI
  • Merit Medical Systems, Inc. MMSI
  • Nevro Corporation NVRO
  • Orthofix Medical OFIX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024April 24, 2025=◇◇◇
2023April 25, 2024=◇◇◇
2022April 27, 2023=◇◇◇
2021April 28, 2022=◇◇◇
2020April 29, 2021=◇◇◇
2019April 30, 2020=◇◇◇
2018April 25, 2019=◇◇◇
2017April 26, 2018=◇◇◇
2016April 27, 2017=◇◇◇
2015April 28, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- David Pacitti (Chief Executive Officer), FY2025 total compensation $9,469,803 (base salary $751,705) [exec_comp, SEC accession 0001104659-26-027106, filed 2026-03-12]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Avanos Medical files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Avanos Medical disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Avanos Medical sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Avanos Medical's disclosed peer group is defensible, who names Avanos Medical back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
359 figures on this page: 349 cited to the filing that reported them, 10 calculated from figures it prints.
349 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001104659-26-027106
    2025 Outside Director Compensation · Director Compensation · Grants of Plan-Based Awards · OUTSTANDING EQUITY AWARDS AS OF DECEMBER 31, 2025 · and 2 more sections
  2. 0001606498-25-000078
    Proposal No. 3. The Company s stockholders approved Proposal No. 3. The votes cast on Proposal No. 3 were as follows
  3. 0001104659-25-023991
    Summary Compensation Table
  4. 0001606498-24-000053
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001104659-24-034942
    Summary Compensation Table
  6. 0001606498-23-000039
  7. 0001606498-22-000047
  8. 0001606498-21-000018
  9. 0001606498-20-000027
  10. 0001606498-19-000025
  11. 0001606498-18-000029
  12. 0001606498-17-000017
  13. 0001606498-16-000059
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Avanos Medical executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/AVNS (accessed 2026).
Short form: data: Velarion

The Avanos Medical brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Avanos Medical and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers Avanos Medical discloses

The companies named in AVNS's own disclosed peer group.

Accuray IncorporatedAngioDynamics, Inc.AtriCure, Inc.Bioventus Inc.CONMED CorporationGlobus Medical Inc.ICU Medical, Inc.Insulet CorporationInteger Holdings CorporationIntegra Lifesciences HoldingLantheus Holdings, Inc.Masimo CorporationMerit Medical Systems, Inc.Nevro CorporationOrthofix Medical

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy